Innovative Health Care Models Prove Cost-Effective Amidst Pandemic Pressures

By Staff Writer

September 26, 2023

During the COVID-19 pandemic, hospitals faced immense pressure. Singapore was also grappling with a dengue outbreak, adding to the strain on hospital capacity. This situation led to the rapid implementation of novel care models to treat patients with acute, low-severity medical conditions.

Two of these models, the hospital-at-home (HaH) and ambulatory care team (ACT) models, were used to treat patients with dengue and chest pain respectively. The HaH model allowed patients to receive care at home, while the ACT model provided timely care in a clinic-style setting at the hospital’s emergency department.

An economic evaluation aimed to compare the personnel cost of these models with conventional hospital inpatient care. The results showed that the HaH and ACT models used less personnel time, resulting in reduced costs.

The HaH model for treating dengue was found to be slightly cheaper than conventional care, with estimated savings of 18 SGD per case. The ACT model for treating chest pain showed more significant savings, with an estimated reduction of 126 SGD per case.

These innovative health care models not only alleviate hospital pressure but also potentially reduce hospital-acquired infections, length of stay, and overall health care expenditure. However, a reliable cost analysis of these models remains a priority.

Reference url

Recent Posts

digital HIV self-testing
        

Cost-Effectiveness of Digital HIV Self-Testing

💡 Is digital innovation the key to enhancing HIV testing in high-prevalence regions?

A recent study reveals that digital HIV self-testing (HIVST) not only proves cost-effective but significantly improves care linkage, particularly among populations with higher HIV test-positivity rates. This data-driven approach could reshape public health strategies in Malawi, South Africa, and Brazil!

Jump into the findings and implications for policy and health equity in our latest article!

#SyenzaNews #digitalhealth #HealthEconomics #costeffectiveness

gene therapy sickle cell
            

NICE Approves Gene Therapy for Sickle Cell: A Breakthrough in Treatment and Health Equity

🌟 Are we on the brink of a cure for sickle cell disease?

The recent approval of a one-off gene therapy by NICE offers hope for individuals suffering from severe sickle cell disease, addressing both health outcomes and economic disparities. This breakthrough not only promises to enhance quality of life but also tackles the socio-economic challenges associated with the disease.

Jump into the full article to learn more about the implications of this gene therapy and its potential impact on the healthcare landscape.

#SyenzaNews #HealthEconomics #HealthcareInnovation #CostEffectiveness

cervical cancer app
       

Cervical Cancer App: Enhancing Screening and Treatment

✨ *Can a mobile app change the future of cervical cancer screening in Kenya?*
A recent clinico-economic model unveils how a cervical cancer app could significantly enhance screening processes and improve treatment outcomes for women in Kenya. This innovative approach not only increases detection rates but also shows long-term cost savings in managing cervical cancer.

Explore the full article to learn how mobile health technology can tackle this pressing public health challenge!

#SyenzaNews #digitalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.